A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab

Rheumatology International

Volumn 32, Issue 12, 2012, Pages 4023-4026

  Kawashiri, Shinya ^a   Kawakami, Atsushi ^a   Sakamoto, Noriho ^a   Ishimatsu, Yuji ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Interstitial lung disease; Pneumocystis pneumonia; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CARBON MONOXIDE; ETANERCEPT; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB;

AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CHRONIC RESPIRATORY FAILURE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG PULSE THERAPY; DYSPNEA; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKAPHERESIS; LUNG DIFFUSION CAPACITY; LUNG EMPHYSEMA; LUNG FUNCTION TEST; MALE; OXYGEN THERAPY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FATAL OUTCOME; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE;

EID: 84872264322     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1525-z     Document Type: Article

References (14)

1. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M et al (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5:1731-1740
2. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T et al (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic beneWt from an x ray readerblinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162-1167
3. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J et al (2009) Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 19:12-19
4. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E et al (2008) TOPTION Investigators. EVect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A doubleblind, placebo-controlled, randomised trial. Lancet 371:987-997
5. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E et al (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968-2980
6. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 69:88-96
7. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516-1523
8. Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O (2007) Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 34:1151-1154
9. Chatterjee S (2004) Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol 33:276-277
10. Villeneuve E, St-Pierre A, Haraoui B (2006) Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 33:1189-1193
11. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H et al (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67:189-194
12. Harigai M, Koike R, Miyasaka N (2007) Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 357:1874-1876
13. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K et al (2009) Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: A retrospective review and case-control study of 21 patients. Arthritis Rheum 61:305-312
14. Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum 54:628-634